Hydradenitis suppurativa: etiology, pathogenesis and treatment

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Hydradenitis suppurativa is a multifactorial disease. The pathogenesis has not been well studied yet. The views about antecedence of lesions of structural elements of the skin are disputable and that is what determines the actuality of scientific studies in this field. The article presents literature review on modern data regarding prevalence and etiology of the disease. The classification of clinical features and Satorius score for quantitating the severity of the disease, the methods of diagnosis (bacteriological, immunopathological and etc.) are suggested. The role of the genetic, comorbid factors, metabolic and hormonal disorders and the immune system part in the development of the disease are discussed. Topical and systemic medications with the primary purpose of reducing bacterial load, elimination offollicular occlusion, normalization of immune response, correction of hormonal status, improvement of skin defects healing, pain syndrome removal, improving the quality of life ofpatients, are suggested for the therapy.

Full Text

Restricted Access

About the authors

S. A Masyukova

Moscow State University of food production

125080, Moscow, Russia
Medical Institute of physicians advanced training

V. V Mordovtseva

Moscow State University of food production

125080, Moscow, Russia
Medical Institute of physicians advanced training

Inna V. Ilina

Moscow State University of food production

Email: Il.inna2012@yandex.ru
125080, Moscow, Russia
Candidate of Medical Sciences, docent of Department of skin and venereal diseases with the course of cosmetology of Medical Institute of physicians advanced training

E. G Sanakoeva

Moscow State University of food production

125080, Moscow, Russia
Medical Institute of physicians advanced training

Z. A Alieva

Moscow State University of food production

125080, Moscow, Russia
Medical Institute of physicians advanced training

D. V Grebenyuk

Moscow State University of food production

125080, Moscow, Russia
Medical Institute of physicians advanced training

Yu. P Sokolova

Moscow State University of food production

125080, Moscow, Russia
Medical Institute of physicians advanced training

References

  1. Михеев Г.Н., Аравийская Е.Р., Соколовский Е.В., Холодилова Н.А. Инверсные акне: современные представления о патогенезе, клинических проявлениях и терапии. Пластическая хирургия и косметология. 2010; 3: 433-8.
  2. Sellheyer K., Krahl D. “Hidradenitis suppurativa” is acne inversa! An appeal to (finally) abandon a misnomer. Int. J. Dermatol. 2005; 44(7): 535-40.
  3. Демьянов С.Л., Корейба К.А., Жирнова Л.Р. Дифференциальная диагностика инфекций кожи и мягких тканей подмышечных областей. Практическая медицина. 2011; 49(1): 160-2.
  4. Масюкова С.А., Гладько В.В., Устинов М.В., Владимирова Е.В., Тарасенко Г.Н., Сорокина Е.В. Бактериальные инфекции кожи и их значение в клинической практике. Consilium medicum. Дерматология. 2004; 6(3): 180-5.
  5. Kurzen H., Kurokawa I., Jemec G.B., Emtestam L., Sellheyer K., Glamarellos-Bourboulis E.J., et al. What causes hidradenitis suppurativa? Exp. Dermatol. 2008; 17(5): 455-6. doi: 10.1111/j.1600-0625.2008.00712_1.x.
  6. Vandenesch F., Eykyn S.J., Etienne J., Lemozy J. Skin and post-surgical wound infections due to Staphylococcus lugdunensis. Clin. Microbiol. Infect. 2009; 47(7): 946-50.
  7. Matusiak Ł., Bieniek A., Szepietowski J.C. Hidradenitis suppurativa markedly decreases quality of life and professional activity. J. Am. Acad. Dermatol. 2010; 62(4): 706-8.
  8. Matusiak L., Bieniek A., Szepietowski J.C. Hidradenitis suppurativa and associated factors: still unsolved problems. J. Am. Acad. Dermatol. 2009; 61(2): 362-5.
  9. Revuz J. Hidradenitis suppurativa. J. Eur. Acad. Dermatol. Venereol. 2009; 23(9): 985-98.
  10. Canoui-Poitrine F., Revuz J.E., Wolkenstein P., Viallette C., Gabison G., Pouget F., et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J. Am. Acad. Dermatol. 2009; 61(1): 51-7.
  11. Sabat R., Chanwangpong A., Schneider-Burrus S., Metternich D., Kokolakis G., Kurek A., et al. Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One. 2012; 71(3): 460-7.
  12. Happle R., Koning A. Smoker’s boils. Dermatology. 2011; 222(3): 282-4. doi: 10.1159/000327923.
  13. Jemec G.B. The concept of ‘smoker’s boils’ is suggestive of a new hypothesis on the pathogenesis of hidradenitis suppurativa. Dermatology. 2011; 222(3): 196-7. doi: 10.1159/000327928.
  14. Kołodziejczak M., Sudoł-Szopińska I., Wilczyńska A., Bierca J. Utility of transperineal and anal ultrasonography in the diagnostics of hidradenitis suppurativa and its differentiation from a rectal fistula. Postepy Hig. Med. Dosw (Online). 2012; 66: 838-42. doi: 10.5604/17322693.1019537.
  15. Attanoos R.L., Appleton M.A., Douglas-Jones A.G. The pathogenisis of hidradenitis suppurativa: a closer look at apocrine and apoeccrine glands. Br. J. Dermatol. 1995; 133(2): 254-8.
  16. Gee B.C., Dawber R.P. Hidradenitis suppurativa. J. R. Soc. Med. 2000; 93(12): 661-2.
  17. Hughes L.E. Pathogenesis, clinical features and management of hidradenitis suppurativa. Ann. R. Coll. Surg. Engl. 1997; 79(2): 309-10.
  18. Dufour D.N., Bryld L.E., Jemec G.B. Hidradenitis suppurativa complicating naevus comedonicus: the possible influence of mechanical stress on the development of hidradenitis suppurativa. Dermatology. 2010; 220(4): 323-5.
  19. Alestas T., Ganceviciene R., Fimmel S., Müller-Decker K., Zouboulis C.C. Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands. J. Mol. Med. (Berl). 2006; 84(1): 75-87.
  20. Fimmel S., Zouboulis C.C. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol. 2010; 2(1): 9-16. doi: 10.4161/derm.2.1.12490.
  21. Lee D.Y., Yamasaki K., Rudsil J., Zouboulis C.C., Park G.T., Yang J.M., Gallo R.L. Sebocytes express functional cathelicidin antimicrobial peptides and can act to kill propionibacterium acnes. J. Invest. Dermatol. 2008; 128(7): 1863-6. doi: 10.1038/sj.jid.5701235.
  22. Gniadecki R., Jemec G.B. Lipid raft-enriched stem cell-like keratinocytes in the epidermis, hair follicles and sinus tracts in hidradenitis suppurativa. Exp. Dermatol. 2004; 13(6): 361-3.
  23. Kamp S., Fiehn A.M., Stenderup K., Rosada C., Pakkenberg B., Kemp K., et al. Hidradenitis Suppurativa - the disease of the absent sebaceous gland? Br. J. Dermatol. 2011; 164(5): 1017-22.
  24. Jemec G.B., Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J. Am. Acad. Dermatol. 1998; 39(6): 971-4.
  25. Harrison B.J., Kumar S., Read G.F., Edwards C.A., Scanlon M.F., Hughes L.E. Hidradenitis suppurativa: evidence for an endocrine abnormality. Br. J. Surg. 1985; 72(12): 1002-4.
  26. Jansen T., Plewig G. What’s new in acne inversa (alias hidradnitis suppurativa)? J. Eur. Acad. Dermatol. 2000; 14(5): 342-3.
  27. Jemec G.B. Clinical practice. Hidradenitis suppurativa. N. Engl. J. Med. 2012; 366(2): 158-64.
  28. Kraft J.N., Searles G.E. Hidradenitis suppurativa in 64 female patients: retrospective study comparing oral antibiotics and antiandrogen therapy. J. Cutan. Med. Surg. 2007; 11(4): 125-31.
  29. von Der Werth J.M., Williams H.C., Raeburn J.A. The clinical genetics of hidradenitis suppurativa revisited. Br. J. Dermatol. 2000; 142(5): 947-53.
  30. Mozeika E., Pilmane M., Nürnberg B.M., Jemec G.B. Tumour necrosis factor-alpha and matrix metalloproteinase-2 are expressed strongly in hidradenitis suppurativa. Acta Derm. Venereol. 2013; 93(3): 301-4. doi: 10.2340/00015555-1492.
  31. Wortsman X., Revuz J., Jemec G.B. Lymph nodes in hidradenitis suppurativa. Dermatology. 2009; 219(1): 22-4. doi: 10.1159/000213064.
  32. Oliveira S.H., Canetti C., Ribeiro R.A., Cunha F.Q. Neutrophil migration induced by IL-1beta depends upon LTB4 released by macrophages and upon TNF-alpha and IL-1beta released by mast cells. Inflammation. 2008; 31(1): 36-46.
  33. Wolk K., Kunz S., Witte E., Friedrich M., Asadullah K., Sabat R. IL-22 increases the innate immunity of tissues. Immunity. 2004; 21(2): 241-54.
  34. Jemec G.B., Hansen U. Histology of hidradenitis suppurativa. J. Am. Acad. Dermatol. 1996; 34(6): 994-9.
  35. Highet A.S., Warren R.E., Staughton R.C., Roberts S.O. Streptococcus milleri causing treatable infection in perineal hidradenitis suppurativa. Br. J. Dermatol. 1980; 103(4): 375-82.
  36. Bergmans B.A., De Strooper B. Gamma-secretases: from cell biology to therapeutic strategies. Lancet Neurol. 2010; 9(2): 215-26. doi: 10.1016/S1474-4422(09)70332-1.
  37. Murdoch D.A. Gram-positive anaerobic cocci. Clin. Microbiol. Rev. 1998; 11(1): 81-120.
  38. Van Rappard D.C., Limpens J., Mekkes J.R. The off-label treatment of severe hidradenitis suppurativa with TNF-α inhibitors: a systematic review. J. Dermatol. Treat. 2013; 24(5): 392-404. doi: 10.3109/09546634.2012.674193.
  39. Jemec G.B., Faber M., Gutschik E., Wendelboe P. The bacteriology of hidradenitis suppurativa. Dermatology. 1996; 193(3): 203-6.
  40. Трякина И.П. Фурункулез и гидраденит как проявление нарушений биоциноза. Медицинский алфавит. 2012; 4(24): 54.
  41. Wollina U., Koch A., Heinig B., Kittner T., Nowak A. Acne inversa (Hidradenitis suppurativa): a review with a focus on pathogenesis and treatment. Indian Dermatol. Online J. 2013; 4(1): 2-11.
  42. Fitzsimmons J.S., Guilbert P.R. A family study of hidradenitis suppurativa. J. Med. Genet. 1985; 22(5): 367-73.
  43. von der Werth J.M., Jemec G.B. Morbidity in patients with hidradenitis suppurativa. Br. J. Dermatol. 2001; 144(4): 809-13.
  44. Gao M., Wang P.G., Cui Y., Yang S., Zhang Y.H., Lin D., et al. Inversa acne (hidradenitis suppurativa): a case report and identification of the locus at chromosome 1p21.1-1q25.3. J. Invest. Dermatol. 2006; 126(6): 1302-6.
  45. Von Laffert M., Stadie V., Wohlrab J., Marsch W.C. Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br. J. Dermatol. 2011; 164(2): 367-71.
  46. Bergmans B.A., De Strooper B. Gamma-secretases: from cell biology to therapeutic strategies. Lancet Neurol. 2010; 9(2): 215-26. doi: 10.1016/S1474-4422(09)70332-1.
  47. Zhang C., Wang L., Chen L., Ren W., Mei A., Chen X., Deng Y. Two novel mutations of the NCSTN gene in Chinese familial acne inverse. J. Eur. Acad. Dermatol. Venereol. 2013; 27(12): 1571-4. doi: 10.1111/j.1468-3083.2012.04627.x.
  48. Miskinyte S., Nassif A., Merabtene F., Ungeheuer M.N., Join-Lambert O., Jais J.P., et al. Nicastrin mutations in French families with hidradenitis suppurativa. J. Invest. Dermatol. 2012; 132(6):1728-30.
  49. Pink A.E., Simpson M.A., Brice G.W., Smith C.H., Desai N., Mortimer P.S., et al. PSENEN and NCSTN mutations in familial hidradenitis suppurativa (acne inversa). J. Invest. Dermatol. 2011; 3(1): 1568-70.
  50. Ingram J.R., Piguet V. Phenotypic heterogeneity in hidradenitis suppurativa (acne inversa): classification is an essential step toward personalized therapy. J. Invest. Dermatol. 2013; 133(6): 1453-6. doi: 10.1038/jid.2012.476.
  51. Giamarellos-Bourboulis E.J., Antonopoulou A., Petropoulou C., Mouktaroudi M., Spyridaki E., Baziaka F., et al. Altered innate and adaptive immune responses in patients with Hidradenitis suppurativa. Br. J. Dermatol. 2007; 156(1): 51-6.
  52. Wiseman M.C. Hidradenitis suppurativa: a review. Dermatol. Ther. 2004; 17(1): 50-4.
  53. Sabat R. IL-10 family of cytokines. Cytokine Growth Factor Rev. 2010; 21(5):315-324.
  54. Dréno B., Khammari A., Brocard A., Moyse D., Blouin E., Guillet G., et al. Hidradenitis suppurativa: the role of deficient cutaneous innate immunity. Arch. Dermatol. 2012; 148(2): 182-6.
  55. Hofmann S.C., Saborowski V., Lange S., Kern W.V., Bruckner-Tuderman L., Rieg S. Expression of innate defense antimicrobial peptides in hidradenitis suppurativa. J. Am. Acad. Dermatol. 2012; 66(6): 966-74.
  56. Matusiak L., Bieniek A., Szepietowski J.C. Increased serum tumour necrosis factoralpha in hidradenitis suppurativa patients: is there a basis for treatment with antitumour necrosis factor-alpha agents? Acta Derm. Venereol. 2009; 89(6): 601-3. doi: 10.2340/00015555-0749.
  57. Scheinfeld N. Hidradenitis Suppurativa in prepubescent and pubescent children. Clin. Dermatol. 2015; 33(3): 316-9. doi: 10.1016/j.clindermatol.2014.12.007.
  58. Vaithianathan R., Hockey P.M., Moore T.J., Bates D.W. Iatrogenic effects of COX-2 inhibitors in the US population: findings from the Medical Expenditure Panel Survey. Drug. Saf. 2009; 32(4): 335-43. doi: 10.2165/00002018-200932040-00007.
  59. Van der Zee H.H., Laman J.D., Boer J., Prens E.P. Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments. Exp. Dermatol. 2012; 21(10): 735-9.

Statistics

Views

Abstract - 88

PDF (Russian) - 0

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions


Copyright (c) 2016 Eco-Vector



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies